Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Exelixis gains
Opinion
Exelixis gains after win in patent fight with MSN over Cabometyx
Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claim of the '349 patent not infringed and not invalid, Judge Richard Andrews ruled,
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
Exelixis, Inc. EXEL announced that the District Court of Delaware has ruled in its favor in the second patent litigation against MSN Laboratories. MSN is seeking approval for its generic product of Exelixis’ cabozantinib.
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A
Exelixis' Wins Court Ruling in Patent-Infringement Lawsuit
A court ruled in favor of Exelixis in the oncology company's patent-infringement lawsuit against MSN Laboratories.
Zacks.com on MSN
2d
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Exelixis EXEL shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
GlobalData on MSN
3d
Exelixis and MSD to trial cancer therapies together in clinical collaboration
US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...
FiercePharma
2d
Exelixis stock rises as key drug Cabometyx withstands patent challenge
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Zacks.com on MSN
1d
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Hosted on MSN
11d
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
Shares of Exelixis, Inc. EXEL have risen 20.7% in the past three months compared with the industry’s growth of 6.3%. The ...
1d
Exelixis: Navigating Patent Challenges and Future Growth Prospects with a Hold Rating
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Zacks.com on MSN
3d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback